Serum and gene expression profile of tumor necrosis factor-α and interleukin-6 in hypertensive diabetic patients: Effect of amlodipine administration

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 1, 2010, Pages 51-59

  Navarro González, Juan F ^a,b   Mora Fernandez C ^a   Gomez Chinchon M ^a   Muros, M ^a   Herrera, H ^a   Garcia, J ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Amlodipine; Cytokines; Diabetes; Hypertension; Peripheral blood mononuclear cells

Indexed keywords

AMLODIPINE; CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM;

EID: 77951729303     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300105     Document Type: Article

References (30)

1. Virdis A, Schiffrin E. Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003; 12:181-187
2. Williams MD, Nadler JL. Inflammatory mechanisms of diabetic complications. Curr Diab Rep 2007; 7:< 242-248
3. Clinton S, Libby P. Cytokines and growth factors in atherogenesis. Arch Path Lab Med 1992; 116:1292-300.
4. Linton M, Babaev V, Gleaves L, Fazio S. A direct role for macrophage LDL receptor in atherosclerotic lesion formation. J Biol Chem 1999; 274:19204-19210
5. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 2006; 95:511-518
6. Mason RP. Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Cerebrovasc Dis 2003; 16(S):11-17
7. Mason RP, Marche P, Hintze T. Novel vascular biology of third-generation L-type calcium channel antagonists. Ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23:2155-2163
8. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine 2000; 12:294-297 (Pubitemid 30449888)
9. Chou T, Yang S, Pei D. Amlodipine inhibits prov inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopolysacharide/interferon-g-stimulated cultured vascular smooth muscle cells. Jpn J Pharmacol 2002; 89:157-163 (Pubitemid 34752301)
10. rd, Sorensen L, Ghali J, Shocken D, Willis P, Bowers J, Cropp A, Pressler M. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Ramdomized Amlodipine Survival Evaluation. J Am Coll Cardiol 1997; 30:35-41.
11. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470 (Pubitemid 29135798)
12. Pickup J, Chusney G, Thomas S, Burt D. Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000; 67:291-300. (Pubitemid 30413937)
13. Temelkova-Kurktschiev T, Siegert G, Bergman S, Henkel E, Koelher K, Jaross W, Hanefeld M. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51:743-749 (Pubitemid 34624841)
14. Schram M, Chatuverdi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller J, Stehouwer C; EURODIAB Prospective Complications Study. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: EURODIAB Prospective Complications Study. Diabetes Care 2003; 26:2165-2173
15. Ridker P, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-2153 (Pubitemid 30253042)
16. St-Pierre A, Cantin B, Bergeron M, Pirro M, Dagenais G, Després J, Lamarche B. Inflammatory markers and long-term risk of ischemic heart disease in men. A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 2005; 182:315-321
17. Koenig W, Khuseyinova N, Baumert J, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006; 26:2745-2751
18. Bennet A, van Maarle M, Hallqvist J, Morgenstem R, Frostegard J, Wiman B, Prince J, De Faire U. Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction. Atherosclerosis 2006; 187:408-414 (Pubitemid 43963023)
19. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809
20. Kostulas N, Pelidou S, Kivisäkk P, Kostulas V, Link H. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood, mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999; 30:2174-2179 (Pubitemid 29473266)
21. Akatsu T, Nakamura M, Satoh M, Hiramori K. Increased mRNA expression of tumour necrosis factor-alpha and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction. Clin Sci 2003; 105:39-44. (Pubitemid 36819574)
22. Pitt B, Byington R, Furberg C, Hunninhake D, Mancini G, Miller M, Rilley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102:1503-1510
23. Dahlof B, Sever P, Poulter N, et al: ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366:895-906.
24. Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the coronary angioplasty amlodipine restenosis study (CAPARES). J Am Coll Cardiol 2000; 35:592-599
25. Poulter N, Wedel H, Dahlof B, et al: ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366:907-913
26. Chou T, Yang S, Pei D. Amlodipine inhibits pro-inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopolysaccharide/interferon-g-stimulated cultured vascular smooth muscle cells. Jpn J Pharmacol 2002; 89:157-163 (Pubitemid 34752301)
27. Kaynar K, Ulusoy S, Ovali E, Vanizor B, Dikmen T, Gul S. TGF-b and TNF-a producing effects of losartan and amlodipine on human mononuclear cell culture. Nephrology 2005; 10:478-482 (Pubitemid 41727272)
28. Andrzejczak D, Gorska D, Czarnecka E. Influence of amlodipine and atenolol on lipopolysaccharide (LPS)-induced serum concentrations of TNF-a, IL-1b, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep 2006; 58:711-719
29. Salomon P, Halawa B, Karolko B. Influence of amlodipine on serum levels of some cytokines in patients with congestive heart failure. Pol Arch Med Wewn 2003; 109:149-155 (Pubitemid 36378244)
30. Ersoy C, Imamoglu S, Budak F, Tuncel E, Ertürk E, Oral B. Effect of amlodipine on insulin resistance and tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients. Indian J Med Res 2004; 120:481-488 (Pubitemid 40044920)